Dr. Soo Jin Park, MD

Dr. Park practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Park's NPI, 1821351198, was assigned on June 20, 2012. Dr. Park graduated from Indiana University School Of Medicine in 2012. Dr. Park holds California license 135455.

Dr. Park's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Park's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Park is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Park to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Park practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Park's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Park is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Park's licenses on file in 4 states: California, New Jersey, Missouri and New York.

Dmand AI lists chronic anemia among the conditions Dr. Park treats.

CMS data shows 627 Medicare services from Dr. Park across 3 procedure codes in 2024, for 122 Medicare patients. Medicare paid $46,225 for them.

CMS counts 122 Medicare patients who saw Dr. Park in 2024. The largest group is 65 to 74, with 44 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 23% are also on Medicaid. Their average risk score is 2.46, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Park's median patient age at 69, with 56% women.

In 2024, Dr. Park wrote 35 Medicare Part D claims for 14 patients. 74% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $143,668 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Park for performance year 2024, reported as part of a group. Dr. Park accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Park as offering telehealth.

Dmand AI links 24 papers to Dr. Park, published from 2015 to 2025. 2025 was the busiest year, with 4. The most frequent topics are Hematopoietic Stem Cell Transplantation, Skin Neoplasms and Biomarkers, Tumor. Dr. Park has published most often in Blood Adv. Dr. Park's most frequent co-authors are George Ansstas, MD, John F. Dipersio, MD and Katharine C. Hsu, MD.

Dmand AI links Dr. Park to 5 clinical trials. 3 are still active or recruiting. Conditions studied include Colonic Neoplasms, Uterine Cervical Neoplasms and Colorectal Neoplasms. Kyungpook National University Hospital sponsors the most, 4. Open Payments lists research payments to Dr. Park that name 3 trials.

CMS Open Payments shows 77 general payments to Dr. Park from 16 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 78% of the total. Sun Pharmaceutical Industries Inc. paid the most, $18,595. It also lists 59 research payments totaling $11,357 from 2021 to 2025, naming 3 clinical trials.

Dr. Park graduated from Indiana University School Of Medicine in 2012.

Dr. Park is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.